Q4 2020 Brainstorm Cell Therapeutics Inc Earnings Call Transcript
Greetings and welcome to the BrainStorm Cell Therapeutics' fiscal year-end 2020 earnings call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to introduce your host, Mr. Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.
Thank you, and good morning, everyone. Thank you for joining the BrainStorm Cell Therapeutics call. Before we begin the opening remarks, we'd like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance.
Statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, sufficiency of the company's existing capital resources for continuing operations in 2021 and beyond, the [findings to date] regarding the tolerability and full potential of the NurOwn technology platform, clinical trials of NurOwn and related clinical development
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |